Yes there is potential Competing Interest.
C.A. has received sponsored research support from Bayer AG, and has consulted for ApoPharma; T.K. is an employee of JAPAN TOBACCO INC; M.E. reports grants from Bayer and fees paid to the Charité from AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Amgen, GSK, Sanofi, Covidien, Novartis, Pfizer, all outside the submitted work; B.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson; P.A. works with Fondation Alzheimer (non profit foundation) and Genoscreen (Biotech Company); H.L.L's participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research; M.A.N.’s participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research, he also currently serves on the scientific advisory board for Clover Therapeutics and is an advisor to Neuron23 Inc; N.M. declares institutional research grants to the TIMI Study Group at Brigham and Women’s Hospital from Amgen, Pfizer, Ionis, Novartis, AstraZeneca, and NIH . The TIMI Study Group has received institutional research grant support through Brigham and Women’s Hospital from Abbott, Amgen, Anthos Therapeutics, ARCA Biopharma, Inc., AstraZeneca, Daiichi-Sankyo, Eisai, Intarcia, Ionis Pharmaceuticals, Inc., MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, The Medicines Company, Zora Biosciences, Janssen Research and Development, LLC, Siemens Healthcare Diagnostics, Inc., Softcell Medical Limited; M.S. has consultancies with Althera, Amgen, Anthos Therapeutics, AstraZeneca, Beren Therapeutics, Bristol-Myers Squibb, DalCor, Dr. Reddy’s Laboratories, Fibrogen, IFM Therapeutics, Intarcia, Merck, Moderna, Novo Nordisk, Silence Therapeutics and research grant support through Brigham and Women's Hospital from Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Daiichi-Sankyo, Eisai, Intarcia, Ionis, Medicines Company, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals. C.R. has consultancies with Anthos, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Pfizer. Institutional research grant to the TIMI Study Group at Brigham and Women’s Hospital from Anthos, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Janssen, National Institutes of Health, Novartis. Consultancies with Anthos, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Pfizer. T.H. receives personal fees from Genome Analytics Japan, Inc.; J.C.H is supported by a personal fellowship from the British Heart Foundation (FS/14/55/30806), and acknowledges additional support from the Nuffield Department of Population Health (NDPH), University of Oxford, the British Heart Foundation Centre for Research Excellence, Oxford, and the Oxford Biomedical Research Centre. JCH holds Steering Committee and DSMB positions for various cardiovascular randomized controlled trials, and is a PI/co-PI of research grants from industry related to cardiovascular clinical trials and observational studies that are governed by University of Oxford contracts that protect personal independence. NDPH also has a staff policy of not taking personal payments from industry. Further details can be found at https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf/@@download; S.S. has consultancies with Biogen; P.H. reports grants from German Ministry of Research and Education, during the conduct of the study; research grants from German Ministry of Research and Education, European Union, Charité – Universitätsmedizin Berlin, Berlin Chamber of Physicians, German Parkinson Society, University Hospital Würzburg, Robert Koch Institute, German Heart Foundation, Federal Joint Committee (G-BA) within the Innovationfond, German Research Foundation, Bavarian State (ministry for science and the arts), German Cancer Aid, Charité – Universitätsmedizin Berlin (within Mondafis; supported by an unrestricted research grant to the Charité from Bayer), University Göttingen (within FIND-AF randomized; supported by an unrestricted research grant to the University Göttingen from Boehringer-Ingelheim), University Hospital Heidelberg (within RASUNOA-prime; supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo), outside the submitted work; K.G.H. reports a study grant by Bayer, lecture fees/advisory board fees from Abbott, Alexion, AMARIN, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Bristol-Myers-Squibb, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Pfizer, Premier Research, SUN Pharma and W. L. Gore & Associates; H.J.G has received travel grants and speakers honoraria from Fresenius Medical Care, Neuraxpharm, Servier and Janssen Cilag as well as research funding from Fresenius Medical Care; J.H. is full time employee of Novo Nordisk; E.Y-D. is full time employee of Novo Nordisk
